FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
The Food and Drug Administration issued two alerts Wednesday about electrical problems tied to the company's heart-zapping defibrillator systems and a separate issue with a heart implant used to reduce stroke risk.
The agency said the company's Endotak Reliance defibrillator wires can become calcified, leading to failures in delivering life-saving shocks to the heart, according to the FDA.
Defibrillators are surgically placed in the upper chest, where they monitor irregular heartbeats and use electrical shocks to jolt the heart back to normal.
As of July 24, Boston Scientific has reported 386 serious injuries and 16 deaths associated with this issue, the agency said.
Ten of the deaths were judged to be due to the device failing to function properly, the company said in an email. Four were linked to attempts to surgically remove the devices from patients and two others were deemed unrelated to the implants.
Boston Scientific's wires were distributed between 2002 and 2021 and are no longer available, the company noted in its letter to doctors. Some patients will need to have the devices replaced, though physicians should weigh the risks of the removal procedure.
In a separate notice, the FDA said Boston Scientific recently updated instructions for implanting its Watchman device, which closes a portion of the heart's left atrium to reduce the risk of stroke.
In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the level of anesthesia for patients undergoing the initial implantation procedure. Watchman is an alternative to long-term treatment with blood thinners for patients at increased risk of stroke.
As of July 30, the company has reported 120 serious injuries and 17 deaths related to the issue, the FDA said.
Monday Mornings
The latest local business news and a lookahead to the coming week.
A company investigation concluded that the safety issue 'is not associated with the design or manufacture of any component of the Watchman system.
Heart devices, including defibrillators and other implants, are Boston Scientific's largest business, making up two-thirds of its $5 billion in revenue for the most recent quarter.
Shares of Boston Scientific Corp. fell nearly 1.8 percent Wednesday to close at $102.95 in trading.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
2 hours ago
- National Post
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Article content Article content Article content the United States, Europe, the United Kingdom, and Australia – Article content – European CTA approval to initiate the EMBRACE study in Ireland, Poland, and Greece has been received – Article content – Recently received Medicines and Healthcare products Regulatory Agency ('MHRA') approval to commence EMBRACE in the United Kingdom – Article content – Data from completed Phase 2 MDD study showed that 71% of participants were in remission and 100% of participants responded to treatment at 12 months after just two 16 mg doses of CYB003 – Article content TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced that its Clinical Trial Application ('CTA') has been approved by the Irish Medicines Board, acting as the reference Member state, to initiate the EMBRACE ™ study in Ireland, Poland, and Greece. EMBRACE is the second pivotal study in PARADIGM ®, the Company's Phase 3 multinational program evaluating CYB003, a proprietary deuterated psilocin analog. The Company also recently announced approval from the Medical and Healthcare products Regulatory Agency ('MHRA') to commence EMBRACE in the United Kingdom. Article content CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration ('FDA') for the adjunctive treatment of Major Depressive Disorder ('MDD'). Article content 'Securing European approval to commence the EMBRACE component of PARADIGM – especially on the heels of the recent UK MHRA approval – validates the quality of our Phase 3 clinical development program and reaffirms the strength of our results to date,' said Doug Drysdale, Chief Executive Officer of Cybin. 'We appreciate the trust placed in us by the European Regulatory Agencies and are eager to leverage Europe's well-established clinical trial infrastructure. The EMBRACE study aims to enroll 330 participants who live with moderate to severe MDD and whose symptoms are inadequately controlled with antidepressant treatments. With this additional approval, which enables us to enroll participants in Ireland, Poland, and Greece, we are pleased to expand the reach for this critical research. The rise in mental health disorders knows no borders, and we are committed to an international research base to develop new and more effective treatments for MDD patients everywhere.' Article content Study Design: Article content EMBRACE will enroll 330 patients with moderate to severe MDD (MADRS≥24) who are on a stable dose of antidepressant medication but are responding inadequately. Study participants will be randomized 1:1:1 to receive either CYB003 16 mg, CYB003 8 mg, or inactive placebo. Each study arm will evaluate two doses, administered three weeks apart. The primary endpoint will be change in depressive symptoms as measured by change in MADRS from baseline at six weeks after the first dose. Article content The Phase 3 PARADIGM™ program is expected to enroll a total of 550 participants across three studies: two 12-week randomized, double-blind, placebo-controlled studies, APPROACH™ and EMBRACE, and a long-term extension study, EXTEND. The first Phase 3 trial, APPROACH, is currently dosing and is taking place at approximately 45 clinical sites across the U.S, and patient rollover into EXTEND is ongoing. The second Phase 3 trial, EMBRACE, is expected to enroll participants at approximately 60 clinical sites across the U.S., Europe, and Australia. Participants from APPROACH and EMBRACE will have the opportunity to roll over into EXTEND after completing the 12-week, double-blind, placebo-controlled treatment periods. Article content About Cybin Article content Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Article content With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Article content Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Article content Cautionary Notes and Forward-Looking Statements Article content Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to enroll participants and add additional clinical sites for the PARADIGM program; the Company's plan to enroll 330 participants at 60 clinical sites across the United States, Europe, United Kingdom and Australia for the EMBRACE study; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. APPROACH and EMBRACE are registered trademarks of Cybin IRL Limited, a subsidiary of Cybin. Article content These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the year ended March 31, 2025 and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Article content Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Article content Article content Article content Article content Contacts Article content Investor & Media: Article content Article content Gabriel Fahel Article content Article content Chief Legal Officer Article content Article content Cybin Inc. Article content Article content Article content Article content
Canada News.Net
6 hours ago
- Canada News.Net
Ajovy becomes the first FDA-approved migraine prevention for kids
SILVER SPRING, Maryland: The U.S. Food and Drug Administration has approved Teva Pharmaceuticals' Ajovy for use in children, marking the first time a migraine prevention drug has been cleared for pediatric patients. Ajovy, an injectable treatment already approved for adults, can now be used in children aged six and older who weigh at least 45 kilograms (about 99 pounds), the FDA said this week. The medication is administered once a month. This expanded approval offers a new option for families of children suffering from episodic migraines—severe, recurring headaches that occur frequently enough to disrupt daily life but not on a daily basis. In children, these headaches are often accompanied by nausea, fatigue, and sensitivity to light and sound. Ajovy belongs to a class of medications known as CGRP (calcitonin gene-related peptide) inhibitors, which work by blocking a protein associated with triggering migraines. The drug was first approved in 2018 for adult use and now joins its rivals, Amgen's Aimovig and Eli Lilly's Emgality, in the pediatric space. However, Ajovy is the first among them to secure FDA approval for migraine prevention in children. In clinical trials, the most common side effects in children were pain and redness at the injection site. The FDA noted that the overall safety profile in pediatric patients was similar to that seen in adult studies. More serious but less common side effects include rash, itchiness, and hypersensitivity to the drug. Migraine is one of the most common neurological conditions in children and adolescents, and options for prevention have long been limited. Pediatric neurologists have often relied on off-label prescriptions of adult medications or lifestyle adjustments to manage the condition. The FDA's approval of Ajovy for children could help shift that treatment landscape. Ajovy's pediatric approval also strengthens Teva's position in the competitive CGRP inhibitor market. While Amgen's Aimovig and Lilly's Emgality have gained traction among adult patients.
Winnipeg Free Press
9 hours ago
- Winnipeg Free Press
Cuban animal lovers struggle to feed stray cats and dogs as economic crisis bites
HAVANA (AP) — Every afternoon, 81-year-old Nélida Pérez begins her familiar walk down the cobblestone streets of Old Havana, a procession of hungry cats trailing close behind her. For years, Pérez has taken it upon herself to feed some of the street cats that roam this part of town, which is also one of the most popular tourist spots in the Cuban capital. She once relied on her own food or restaurant donations, but as the island's economic situation worsened and tourism declined, it has become increasingly difficult to provide for them. 'I have never in my life asked anyone for a plate of food to feed my cats,' Pérez told The Associated Press. 'Now I see myself in difficulties because there is no tourism and there is an economic crisis.' Since 2020, Cuba has faced a worsening economic crisis, driven by COVID-19 shutdowns, stricter U.S. sanctions, and an internal monetary reform that triggered inflation. Although the government provides vaccines, sterilization and some free clinics, it does not have the means to provide shelter and food for street cats and dogs. While official data is unavailable, activists say that many pet lovers have turned their homes — even small apartments — into shelters, but they are struggling to keep up with the demand and provide adequate care. 'The streets will kill them,' said Bárbara Iglesias, a 51-year-old pharmacist who adopted five dogs and has rescued and found homes for a dozen others. Iglesias explained that the hardest part is getting food. A 20-kilo (44-pound) bag of dog food, which lasts one dog for about 45 days, costs around $80 — a sum that is out of reach for most. This forces people to feed animals with pig organ meat (offal), chicken parts or mince meat — which are also not easy to obtain. On top of that, annual vaccines cost about $20 and a vet visit is another $10, all while the average monthly salary on the island is only about $12. Experts say that the abandonment of animals in Cuba is a result of several factors, including rising food and medicine prices, the migration of hundreds of thousands of Cubans in the last five years, and a high mortality rate among older adults. 'People are more focused on their problems, which are numerous: Cubans don't have water, they don't have electricity, and getting food is becoming increasingly difficult,' said Annelie González, one of the leaders of the Aldameros Project, a cat colony located in a park in Havana's historic center. 'Having an animal in your care involves feeding and caring,' said González, 36, who works as a restaurant manager and spends much of her income on the cats. She and a small group of volunteers began feeding 15 cats in Aldameros Park at the beginning of the pandemic. Today, they care for more than 150. Over the years, through their own efforts and some donations, they were able to install water pumps, pens for special cases, and cages for the kittens. González points to a number that she said reveals the shocking scale of the problem: at the start of the decade, roughly three abandoned cats appeared in the park each week. This year, that figure has soared to 15 per day. Back in Old Havana, Pérez recounts with sadness how she has seen people mistreat, beat and even kill stray cats. 'As long as I'm alive and healthy, and people help me,' she vowed, 'I'll always find them something to eat.' ____ Follow AP's coverage of Latin America and the Caribbean at
